Fierce Pharma

JUNE 3, 2024

As Japanese chemical giant Asahi Kasei continues its foray into the biopharma contract manufacturing space, the company’s biologics CDMO is expanding its offerings to include starting materials for | Asahi’s U.S. As part of the pDNA pivot, Bionova is setting up a new facility in The Woodlands, Texas.

DNA 80

DNA Gene Therapy Contract Manufacturing Gene 80

BioPharma Reporter

OCTOBER 20, 2022

Forge Biologics has added plasmid DNA manufacturing to its roster of services, enabling it to vertically integrate its production process.

DNA 73

DNA Manufacturing Gene Therapy Production 73

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

The Pharma Data

SEPTEMBER 11, 2021

By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip.

Antibody 52

Antibody DNA Containment Manufacturing 52

The Pharma Data

JANUARY 20, 2021

The first target market for CureLab Veterinary’s patented DNA therapeutics will be to treat cancer in dogs and cats. In published studies, CureLab Veterinary successfully treated breast cancer in 10 out of 11 dogs using the company’s DNA therapeutic. The company expects to be profitable within three years.

DNA 40

DNA Contract Manufacturing Marketing Production 40

Roots Analysis

JANUARY 14, 2024

Usually, the desired gene, such as human insulin gene, when inserted into the plasmid of the host cell uses transcriptional and translational machinery of the host to express itself. It is worth mentioning that in vitro gene expression requires a suitable host for the production of a specific gene product.

Contract Manufacturing 40

Contract Manufacturing Protein Manufacturing Production 40

Drug Discovery Today

OCTOBER 19, 2020

Former Lonza President of Biologics Manufacturing joins to continue rapid expansion of DNA contract manufacturing; Touchlight’s synthetic dbDNA in high demand as starting material in the manufacture of advanced therapies such as mRNA vaccines and cell and gene therapies

DNA 45

DNA Contract Manufacturing Gene Therapy Manufacturing 45